Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Extracellular vesicle-mediated cell-cell communication in keloids and hypertrophic scars: mechanisms, methodological caveats, and therapeutic perspectives

Lu B., Jin J., Jin W., Yuan X., Jin Z.

Narrative Review on Scar, Chronic Inflammation, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Cell Dev Biol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42306298
PMCID
PMC13265475
DOI
10.3389/fcell.2026.1818463

Abstract (original English)

Pathological scarring, including keloids and hypertrophic scars, remains a major clinical challenge characterized by persistent fibroblast activation, excessive extracellular matrix deposition, chronic inflammation, and aberrant tissue remodeling. Although current treatments have improved management, high recurrence rates and variable outcomes indicate that the underlying mechanisms remain incompletely understood. Extracellular vesicles (EVs), especially small extracellular vesicles (sEVs), are increasingly recognized as mediators of intercellular communication in fibrotic skin disorders. However, according to MISEV recommendations, the term "exosome" should be used cautiously unless endosomal origin is specifically demonstrated. In pathological scars, EV-/sEV-mediated signaling has been implicated in fibroblast activation, immune dysregulation, angiogenic imbalance, and extracellular matrix remodeling through cargo transfer among fibroblasts, keratinocytes, endothelial cells, immune cells, and mesenchymal stromal/stem cells. Reported downstream pathways include TGF-β/Smad, Wnt/β-catenin, PI3K/Akt, and NF-κB. However, the strength of evidence varies substantially, as many conclusions are based on in vitro studies or correlative omics analyses rather than direct causal experiments. In addition, differences in EV isolation and characterization methods may significantly affect rep

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research